Quarterly ResultMay 12, 2026, 04:52 PM
Atea Pharmaceuticals Q1 Net Loss $(45.4)M; R&D Up 39%
AI Summary
Atea Pharmaceuticals reported a net loss of $(45.4) million for the first quarter of 2026, an increase from $(34.3) million in the prior year, primarily due to a 39% rise in research and development expenses. The company continues its Phase 3 clinical development for its HCV product candidate, with topline results for C-BEYOND expected mid-2026 and C-FORWARD by year-end 2026, targeting an NDA submission in March 2027. Atea also plans to initiate Phase 1 clinical development for its HEV candidate, AT-587, in mid-2026, and maintains a cash runway sufficient for at least the next twelve months.
Key Highlights
- Net loss for Q1 2026 was $(45.4) million, up from $(34.3) million in Q1 2025.
- Research and development expenses increased by 39% to $41.1 million in Q1 2026.
- General and administrative expenses decreased by 27.3% to $6.9 million in Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $256.0 million as of March 31, 2026.
- Company expects topline results for HCV Phase 3 C-BEYOND in mid-2026.
- HCV Phase 3 C-FORWARD enrollment completion expected mid-2026, topline results year-end 2026.
- Target NDA submission for HCV product candidate is March 2027.
- Initiation of Phase 1 clinical development for HEV candidate AT-587 anticipated mid-2026.
Price Impact
More from AVIR